Literature DB >> 8850302

Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole.

J B Park1, L Imamura, K Kobashi.   

Abstract

Urease is an important virulence factor of pathogenicity of gastric Helicobacter pylori. The inhibition of H. pylori urease by the novel proton pump inhibitor, rabeprazole, was investigated kinetically. It was found to act as an irreversible noncompetitive inhibitor of the enzyme. The inhibitory potency of rabeprazole was dependent on the pH of reaction mixture and its Ki values were 0.14 microM (pH 5.0), 0.34 microM (pH 7.0) and 6.10 microM (pH 8.5). Progressive inactivation of urease by rabeprazole initially proceeded according to pseudo-first-order kinetics with respect to the remaining enzymatic activity at pH 7.0 and 37 degrees C, with a second-order rate constant of 0.0017 microM-1 s-1. When the inactivation half-life was plotted versus the reciprocal of the rabeprazole concentration, a straight line was obtained with a slope of -3.12. From an Arrhenius-plot of the temperature-dependence of the inactivation (over the range of 5-37 degrees C), an activation energy of 13.2 kcal/mol was calculated. Recovery of activity was incomplete for H. pylori urease inhibited by rabeprazole, suggesting that the rabeprazole-urease complex is very stable.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8850302     DOI: 10.1248/bpb.19.182

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  9 in total

1.  Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  Vandana Singh; Vaneet Arora; M Jahangir Alam; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.

Authors:  Y Kawakami; T Akahane; M Yamaguchi; K Oana; Y Takahashi; Y Okimura; T Okabe; A Gotoh; T Katsuyama
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 3.  Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Rabeprazole: a review of its use in acid-related gastrointestinal disorders.

Authors:  H D Langtry; A Markham
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

Review 5.  Medicinal plant activity on Helicobacter pylori related diseases.

Authors:  Yuan-Chuen Wang
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 6.  Rabeprazole.

Authors:  A Prakash; D Faulds
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

7.  A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori.

Authors:  N Tsutsui; I Taneike; T Ohara; S Goshi; S Kojio; N Iwakura; H Matsumaru; N Wakisaka-Saito; H M Zhang; T Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Synthesis, urease inhibition, antioxidant, antibacterial, and molecular docking studies of 1,3,4-oxadiazole derivatives.

Authors:  Muhammad Hanif; Khurram Shoaib; Muhammad Saleem; Nasim Hasan Rama; Sumera Zaib; Jamshed Iqbal
Journal:  ISRN Pharmacol       Date:  2012-08-13

9.  In-silico design, synthesis, ADMET studies and biological evaluation of novel derivatives of Chlorogenic acid against Urease protein and H. Pylori bacterium.

Authors:  Ritu Kataria; Anurag Khatkar
Journal:  BMC Chem       Date:  2019-03-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.